Feb 7th 2023 - Mar 21st 2023
It’s not just the efficacy and safety of the produ... See more
The analyst comments "TGTX stock is up >15... See more
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.Feb 7th 2023 - Mar 21st 2023
We're really the only viable tool for accurate... See more
Our technology gives you unparalleled insight into... See more
$COST almost!
$COST this dude 🤡🤣🤣🤣
$COST The bullish trend in the options market suggests a positive outlook for the stock We are seeing the $450 CALL having heavy activity which expire in 38 days.
$COST 💵long 💅
$COST 🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣🤣
$COST nice wedge here 🫡🔒 all I gottta say 🤫
$COST Love Costco as much as anyone
$COST 2hr looking bullish, she wanna touch the 200 day which is 296, juicy
$COST The chart points towards an optimistic outlook for the stock.
$COST Always a buy in the 470s, congratulations to those who got it this a.m.
It’s not just the efficacy and safety of the product, it is the less cost for hospital/infusion, due to one hour infusion and the huge difference in price.
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Each treatment cost under $10k per treatment.
Each treatment cost under $10k per treatment.
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
We're really the only viable tool for accurate, easy to use, cost effective, complete yield access to large SVs.
Our technology gives you unparalleled insight into genetic abnormalities, allowing for earlier interventions and ultimately saving lives and healthcare costs.
but Bionano's OGM has been shown to be far superior to those tools in accuracy, labor required and ease of use, diagnostic yield, and overall cost.
Only OGM by Bionano can detect large SVs virtually error free, easily, with more diagnostic yield than legacy cyto tools, and cost effectively.
He or she strives to ensure on-time delivery, low transportation costs and inventory accurate.
We are just too unique, powerful, useful and cost effective not to dominate broad and big areas of genetics research and diagnosis.
$BNGO heres the proof we are faster more accurate & more cost effective
$BNGO dna 🧬 saparating and imaging with high throughput and low cost. LFG
Saved cost of the company .
